FLT3 and acute myeloid leukemia: Although targeted inhibitory drugs or antibodies, such as IDH1/IDH2, FLT3, CD33, CD123 and BCL2, can greatly prevent relapse and improve the efficacy of treatment for AML [22], new mutation points are rapidly and continuously emerging because of drug resistance and the likelihood of relapse.